ATCC Number： HB-9459?
運輸方式： 凍存運輸
是否是腫瘤細胞： 0
物種來源： 小鼠
細胞形態： **樣
**類型： mouse IgG1 kappa
數量： 大量
生長狀態： 懸浮生長
Designations: CC 49 [CC-49, CC49]
Depositors: The United States of America
Isotype: mouse IgG1 kappa
CC 49細胞Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma)
Morphology: lymphoblast
Cellular Products: immunoglobulin; monoclonal antibody; against TAG-72 human tumor associated glycoprotein
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments: CC 49細胞Animals were immunized with affinity purified TAG-72 from LS 174T cells (see ATCC CL-188).
Spleen cells were fused with NS-1 mouse myeloma cells.
The antibody binds to TAG-72 with an affinity constant of 20 X 10 exp9 liter/mol.
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate, 85%; heat-inactivated fetal bovine serum, 15%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10(5) viable cells/ml.
CC 49細胞Interval: Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium supplemented with 7.5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
References: 22091: CC 49細胞Schlom J, Colcher D. Second generation monoclonal antibodies having binding specificity to TAG-72 and human carcinomas and methods for employing the same. US Patent 5,512,443 dated Apr 30 1996
